Drug Trial Radar · NCT05084508
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Feb 3, 2022
Primary completion
Feb 9, 2024
Study completion Jun 13, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.
Conditions
- Chickenpox
Interventions
Investigational varicella vaccine low potencyBiological
1 dose of a low-potency investigational varicella vaccine administered subcutaneously.
Investigational varicella vaccine medium potencyBiological
1 dose of a medium-potency investigational varicella vaccine administered subcutaneously.
Investigational varicella vaccine high potencyBiological
1 dose of a high-potency investigational varicella vaccine administered subcutaneously.
Licensed varicella vaccine Lot 1Biological
1 dose of a licensed varicella vaccine of Lot 1 administered subcutaneously.
Licensed varicella vaccine Lot 2Biological
1 dose of a licensed varicella vaccine of Lot 2 administered subcutaneously.
Measles, mumps, and rubella vaccineBiological
1 dose of a measles, mumps, and rubella vaccine administered subcutaneously.
Hepatitis A vaccineBiological
1 dose of a hepatitis A vaccine administered intramuscularly.
13-valent pneumococcal conjugate vaccineBiological
1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentrations of Anti-varicella Zoster Virus (VZV) Glycoprotein E (gE) AntibodiesTime frame: At Day 43
Locations
51 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Bryant, Arkansas
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Bellflower, California
GSK Investigational Site
Downey, California
GSK Investigational Site
Foothill Ranch, California
GSK Investigational Site
Huntington Park, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
West Covina, California
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Idaho Falls, Idaho
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Gulfport, Mississippi
GSK Investigational Site
Bridgeton, Missouri
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
East Syracuse, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Dayton, Ohio
GSK Investigational Site
Fort Washington, Pennsylvania
GSK Investigational Site
Barnwell, South Carolina
GSK Investigational Site
Tullahoma, Tennessee
GSK Investigational Site
Corpus Christi, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Dickinson, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
McAllen, Texas
GSK Investigational Site
Pflugerville, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Layton, Utah
GSK Investigational Site
Provo, Utah
GSK Investigational Site
Roy, Utah
GSK Investigational Site
South Jordan, Utah
GSK Investigational Site
St. George, Utah
GSK Investigational Site
Syracuse, Utah
GSK Investigational Site
Charlottesville, Virginia
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.